<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

November 8, 2019

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

AffyImmune Therapeutics announced FDA approval of their investigational new drug (IND) for AIC100, a CAR-T cell therapy aimed at treating patients with advanced thyroid cancer. The first-in-human phase I study will be sponsored by Weill Cornell Medical Center. Yourway is anticipating a surge in clinical trials exploring these advanced therapies, and is prepared to support any customers for their unique needs.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat
Come chat with us!
Hello! How can I help you?